Meropenem Dosing and Clinical Guidance
For adult patients with normal renal function, administer meropenem 1 gram IV every 8 hours for intra-abdominal infections and 500 mg IV every 8 hours for complicated skin and skin structure infections, with dose escalation to 1 gram every 8 hours when treating Pseudomonas aeruginosa. 1
Standard Dosing Regimens
Adults with Normal Renal Function
- Complicated intra-abdominal infections: 1 gram IV every 8 hours 2, 3, 1
- Complicated skin/soft tissue infections: 500 mg IV every 8 hours 2, 1
- Increase to 1 gram every 8 hours for P. aeruginosa 1
- Meningitis (when ESBL suspected): 2 grams IV every 8 hours 4
Administration Methods
Administer as 15-30 minute infusion or as 3-5 minute IV bolus for 1 gram doses. 1 However, emerging evidence strongly supports extended infusion strategies in critically ill patients to optimize pharmacokinetic/pharmacodynamic targets 5, 6, 7.
For critically ill patients or those with high-MIC organisms (≥2 mg/L), use extended 3-4 hour infusions or continuous infusion to maximize time above MIC. 5, 6, 7 This approach significantly improves target attainment, particularly when aiming for 100% fT>MIC, which may be necessary in severe infections 6.
Renal Dose Adjustments
Meropenem clearance is directly proportional to creatinine clearance, making renal function the primary determinant of dosing. 1, 8, 9
Dosing by Creatinine Clearance (CrCl)
| CrCl (mL/min) | Dose | Interval |
|---|---|---|
| >50 | Standard dose (500 mg or 1 g) | Every 8 hours |
| 26-50 | Standard dose | Every 12 hours |
| 10-25 | Half standard dose | Every 12 hours |
| <10 | Half standard dose | Every 24 hours |
Special Renal Considerations
- Augmented renal clearance (CrCl ≥90 mL/min): Standard regimens are suboptimal 9. Consider 6 g/day total dose with extended infusion or continuous infusion 7, 9
- CrCl 60-90 mL/min: Increase to 6 g/day to achieve adequate MIC coverage 9
- Continuous renal replacement therapy (CRRT): Dosing depends on effluent rate, but generally 1 gram every 8-12 hours 9, 10
- Prolonged intermittent RRT: 750-1000 mg every 8-12 hours depending on session duration and frequency 10
Critical pitfall: Age alone does not affect meropenem pharmacokinetics after accounting for renal function 8. Do not reduce doses based solely on advanced age—adjust only for measured renal function.
Duration of Therapy
Duration should be infection-specific and response-guided, not arbitrarily fixed. 2, 3
- Complicated intra-abdominal infections: 5-10 days 2, 3, 11
- Complicated skin/soft tissue infections: 5-14 days 2, 11
- Bloodstream infections: 7-14 days 11
- Hospital-acquired/ventilator-associated pneumonia: 10-14 days 11
- Meningitis (Gram-negative): 21 days 4
Shorter durations (5-7 days) are appropriate when source control is achieved and clinical response is satisfactory. 2, 3
Contraindications
Absolute contraindication: Known hypersensitivity to meropenem, other carbapenems, or anaphylactic reactions to any β-lactam antibiotic. 1
Relative Contraindications and Warnings
- Severe cutaneous adverse reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported 1
- CNS toxicity/seizures: Risk increases with:
- CNS disorders or history of seizures
- Renal impairment without dose adjustment
- Doses exceeding 2 grams every 8 hours 1
Critical drug interaction: Do NOT co-administer with valproic acid or divalproex sodium. 1 Meropenem reduces valproic acid serum concentrations by 60-100%, potentially precipitating breakthrough seizures within 48 hours 1. If a patient requires both medications, switch to an alternative antibiotic class (not another carbapenem) 1.
- Probenecid co-administration: Not recommended as it inhibits renal excretion and increases meropenem levels 1
Pharmacokinetic/Pharmacodynamic Optimization
The conventional target of 40% fT>MIC may be insufficient for critically ill patients. 6 Recent evidence suggests:
- Standard infections: Target 40% fT>MIC 2, 6
- Critically ill patients: Target 75-100% fT>MIC 6, 7
- Drug-resistant organisms: Target 100% fT>4×MIC 6, 7
To achieve aggressive targets (100% fT>MIC) for organisms with MIC ≥2 mg/L, use continuous infusion or extended 3-4 hour infusions. 5, 6, 7 Standard 30-minute infusions achieve only 49.5% probability of target attainment versus 95.3% with continuous infusion 7.
Continuous Infusion Dosing
For critically ill patients requiring maximal exposure:
- Normal renal function: 3 grams/24 hours continuous infusion 7
- Augmented renal clearance: 6-10.5 grams/24 hours continuous infusion 7, 9
- Renal impairment: Adjust total daily dose proportionally to CrCl 7
Additional benefit: Extended infusion of meropenem when combined with colistin reduces acute kidney injury incidence (24.7% vs 39.7%, p=0.006) and severity compared to intermittent infusion 12.
Therapeutic Drug Monitoring
Consider therapeutic drug monitoring in critically ill patients, those with augmented renal clearance, obesity, or when treating high-MIC organisms. 6, 7, 13 Target trough concentrations depend on MIC: